Article
Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.
The oncologist - 8 Feb 2023
Li Jian, Zhang Xinhua, Deng Yanhong, Wu Xin, Zheng Zhichao, Zhou Yongjian, Cai Shirong, Zhang Yanqiao, Zhang Jun, Tao Kaixiong, Cui Yuehong, Cao Hui, Shen Kuntang, Yu Jiren, Zhou Ye, Ren Wenxiao, Qu Chenglin, Zhao Wanqi, Hu Jin, Wang Wei, Yang Jason, Shen Lin
Abstract excerpt
BACKGROUND: Avapritinib is a type 1 kinase inhibitor designed to potently and selectively inhibit oncogenic KIT/PDGFRA mutants by targeting the kinase active conformation. This multicenter, single-arm, open-label, phase I/II bridging study of NAVIGATOR in Chinese patients evaluated the safety and the antineoplastic activity of avapritinib in Chinese patients with unresectable/metastatic gastrointestinal stromal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.